Medipost Co Ltd

Medipost Co Ltd has a liquidity position characterized by a current ratio of 1.33, indicating a moderate ability to meet short-term obligations with its current assets. The company holds KRW 76,928,614,430 in cash and equivalents, which is a significant portion of its total assets of KRW 431,550,932,710. However, the company's operating cash flow is negative at KRW -57,145,549,590, and its free cash flow is also negative at KRW -83,282,272,770, suggesting a reliance on external financing or asset sales to fund operations. Profitability metrics for Medipost are weak, with a return on equity of -0.3429 and a return on assets of -0.1979, both significantly below the industry median for biotechnology and medical research firms. The company reported a net loss of KRW -85,398,012,010 and an operating loss of KRW -83,167,889,230, indicating a challenging financial performance. Gross profit of KRW 45,436,444,410 is insufficient to cover operating expenses, contributing to the net loss. Medipost's revenue is concentrated in a few key segments, with no detailed breakdown provided in the available data. The company's geographic exposure is primarily within South Korea, with no significant international revenue streams disclosed. This concentration may expose the company to regional economic and regulatory risks. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The operating loss and negative cash flows suggest a need for strategic adjustments to achieve sustainable growth. The company's capital expenditure of KRW -3,277,199,200 indicates some investment in infrastructure, but the scale is relatively small compared to the overall financial position. Risk factors for Medipost include a low liquidity rating and the potential for dilution, although no immediate filing-based liquidity or dilution flags were detected. The company's debt-to-equity ratio of 0.19 suggests a conservative capital structure, but the negative operating cash flow could pressure liquidity if financing conditions deteriorate. The absence of detailed risk disclosures in recent filings indicates a need for further scrutiny of the company's risk management practices. Recent events and filings for Medipost do not show any significant developments that would impact its financial position or strategic direction. The company's financial statements and disclosures are consistent with a focus on maintaining liquidity and managing debt levels. No major regulatory actions or business transformations were reported in the available data.